0001209191-23-025474.txt : 20230424 0001209191-23-025474.hdr.sgml : 20230424 20230424193155 ACCESSION NUMBER: 0001209191-23-025474 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230314 FILED AS OF DATE: 20230424 DATE AS OF CHANGE: 20230424 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Liao Carrie CENTRAL INDEX KEY: 0001899817 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40360 FILM NUMBER: 23841305 MAIL ADDRESS: STREET 1: C/O MIND MEDICINE INC. STREET 2: ONE WORLD TRADE CENTER, SUITE 8500 CITY: NEW YORK STATE: NY ZIP: 10007 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mind Medicine (MindMed) Inc. CENTRAL INDEX KEY: 0001813814 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1166 ALBERNI STEET STREET 2: SUITE 1604 CITY: VANCOUVER STATE: A1 ZIP: V6E 3Z3 BUSINESS PHONE: (212) 220-6633 MAIL ADDRESS: STREET 1: 1166 ALBERNI STEET STREET 2: SUITE 1604 CITY: VANCOUVER STATE: A1 ZIP: V6E 3Z3 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0407 4/A 2023-03-14 2023-03-17 0 0001813814 Mind Medicine (MindMed) Inc. MNMD 0001899817 Liao Carrie C/O MIND MEDICINE (MINDMED), INC. ONE WORLD TRADE CENTER, SUITE 8500 NEW YORK NY 10007 0 1 0 0 Chief Accounting Officer 0 Common Shares 2023-03-14 4 A 0 75000 0.00 A 101895 D These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 14, 2023, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. Explanatory Note: This Amendment on Form 4/A is being filed to amend the Form 4 filed on March 17, 2023, solely to adjust the number of securities included in Table I under "Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)" to give effect for the 15-for-1 reverse share split the Company effected on August 26, 2022. /s/ Robert Barrow, Attorney-in-Fact 2023-04-24